LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

Начало・Списък с акции・Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

385.6 1

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

384.17

Максимум

386.45

Ключови измерители
By Trading Economics
Приходи	387M 1B
Продажби	195M 3B
P/E Средно за сектора	27.25 35.69
EPS	4.06
Марж на печалбата	34.84
Служители	6,100
EBITDA	641M 1.4B

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+26.05% upside

Дивиденти
By Dow Jones
Следващи печалби	3.11.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-23B 98B
Предишно отваряне	384.6
Предишно затваряне	385.6

Настроения в новините

By Acuity

47%

53%

126 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

428.545 / 498.65 Подкрепа & съпротива

Vertex Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.08.2025 г., 00:05 ч. UTC

Горещи акции

Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl

4.08.2025 г., 21:21 ч. UTC

Печалби

Значими двигатели на пазара

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4.08.2025 г., 20:45 ч. UTC

Печалби

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

5.05.2025 г., 21:00 ч. UTC

Печалби

Vertex Pharmaceuticals 1Q Sales Rise, Profit Falls on Impairment Charge

5.08.2025 г., 20:44 ч. UTC

Печалби

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5.08.2025 г., 18:17 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5.08.2025 г., 15:25 ч. UTC

Печалби

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5.08.2025 г., 14:12 ч. UTC

Печалби

Vertex Stock Tumbles After Strong Earnings. What's Spooking Investors. -- Barrons.com

5.08.2025 г., 11:27 ч. UTC

Печалби

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5.08.2025 г., 10:55 ч. UTC

Печалби

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5.08.2025 г., 10:36 ч. UTC

Печалби

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5.08.2025 г., 10:18 ч. UTC

Печалби

Vertex Stock Tumbles 15% After Strong Earnings. What's Spooking Investors. -- Barrons.com

4.08.2025 г., 20:15 ч. UTC

Печалби

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4.08.2025 г., 20:14 ч. UTC

Печалби

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4.08.2025 г., 20:14 ч. UTC

Печалби

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4.08.2025 г., 20:14 ч. UTC

Печалби

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4.08.2025 г., 20:13 ч. UTC

Печалби

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4.08.2025 г., 20:01 ч. UTC

Печалби

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4.08.2025 г., 20:01 ч. UTC

Печалби

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4.08.2025 г., 20:01 ч. UTC

Печалби

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4.08.2025 г., 20:01 ч. UTC

Печалби

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

6.05.2025 г., 16:31 ч. UTC

Печалби

Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why. -- Barrons.com

5.05.2025 г., 20:03 ч. UTC

Печалби

Vertex Pharmaceuticals Sees 2025 Rev $11.85B-$12B >VRTX

5.05.2025 г., 20:01 ч. UTC

Печалби

Vertex Pharmaceuticals 1Q Net $646.3M >VRTX

5.05.2025 г., 20:01 ч. UTC

Печалби

Vertex Pharmaceuticals 1Q Rev $2.77B >VRTX

5.05.2025 г., 20:01 ч. UTC

Печалби

Vertex Pharmaceuticals 1Q EPS $2.49 >VRTX

5.05.2025 г., 20:01 ч. UTC

Печалби

Vertex Pharmaceuticals 1Q Adj EPS $4.06 >VRTX

27.04.2025 г., 11:00 ч. UTC

Топ новини

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street -- WSJ

11.04.2025 г., 09:30 ч. UTC

Топ новини

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

28.02.2025 г., 12:00 ч. UTC

Топ новини

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Vertex Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

26.05% нагоре

12-месечна прогноза

Среден 486.24 USD 26.05%

Висок 624 USD

Нисък 401 USD

Според 25 анализатори от Wall Street, предложили 12-месечна ценова цел за Vertex Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

25 ratings

Купи

Задържане

Продай

Според 25 анализатори, дали борсови рейтинги на Vertex Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

428.545 / 498.65Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Настроение

By Acuity

126 / 371 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.